An interventional study of Multicomponent delirium-risk prevention bundle in Delirium, Cognitive Impairment and Perioperative/Postoperative Complications, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Delirium with a site in Canada — 16 open to participants now, 24 under way, 2 of them phase 3. Delirium · Canada.
Among the 80 studies in Delirium with a site in Canada, this one is the 13th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2021, is one of 33 with no phase, reaches primary completion later than 8 of the 23 other live ones, and was the 64th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →16 of the 80 studies in Delirium with a site in Canada are open now. Recruiting first, the newest first:
University of Calgary · Sites in Canada
Ages up to 18
Queen's University · Sites in Canada
Ages 18+ · Healthy volunteers
Mount Sinai Hospital, Canada · Sites in Canada, United States
Ages 60+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Ciusss de L'Est de l'Île de Montréal · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 7 · Phase 4 5
First in 2003; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 88 across the 53 interventional studies, 130 across the 27 observational. Of the 42 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 80 have an industry lead sponsor. The 10 most frequent:
Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sunnybrook Health Sciences Centre has 5 studies filed under Delirium — fewer than ten, so there is no comparison to draw.
7 of the studies in Delirium with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07051096University of British ColumbiaResponsive Nature-Driven Imagery to Reduce Delirium After Cardiac Surgery | 2026-12 |
| NCT07562048University of CalgaryTherapeutic Cuddling in Critically Ill Children | 2026-12 |
| NCT05713877Ciusss de L'Est de l'Île de MontréalMelatonin for Treatment of Delirium in Critically Ill Adult Patients | 2026-12-30 |
| NCT06027788Icahn School of Medicine at Mount SinaiCTSN Embolic Protection Trial | 2027-04-01 |
| NCT06648681University of British ColumbiaLemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies in Delirium with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cognitive complications, that is problems with thinking and memory, are incredibly common after surgery, occurring in 10-50% of all older surgical patients. These complications can take different forms, but one of the most common is postoperative delirium (POD), a short-term state of confusion. In addition to being stressful for patients and their families, POD is linked to longer hospital stays, increased costs, higher mortality rates and other problems after surgery. Despite this, POD is often not recognized by doctors and there are currently no effective medications to treat POD. However, simple strategies such as helping patients to sleep properly and remain hydrated, have been shown to help.
This study is testing if a delirium-reduction program will reduce postoperative delirium (POD) in older surgical patients. The investigators will first test memory and thought processes before surgery to find people who are most likely to develop POD. Once these people have been identified, they will be enrolled in a program which includes recommendations for their care team (e.g. surgeon, anesthesiologist, nurses) as well as educational materials for them and their family related to things that can be done to prevent delirium. By identifying at-risk patients and making sure that their doctors and caregivers are aware of how to prevent delirium, the investigators expect that this study will make surgery safer for older surgical patients.
Postoperative delirium (POD), an acute, reversible disturbance in brain function characterized by fluctuating levels of consciousness, attention and cognition is a common postoperative complication in older surgical patients. POD is associated with increased morbidity, mortality, and risk of dementia; in addition to longer hospital stays and increased healthcare costs. Despite this, POD frequently goes unrecognized by healthcare providers and is often poorly proactively managed. There are currently no effective pharmacological treatments for POD, although non-pharmacological prevention strategies (e.g. promoting sleep hygiene, hydration, and early mobilization) have proven effective.
This will be a two-phase, prospective, observational comparative study in patients (age ≥60) presenting for major, elective surgical procedures with an expected postoperative stay ≥1 day(s). In both phases, baseline cognitive screening will be used to identify individuals with evidence of pre-existing cognitive impairment (pre-CI), a key risk factor for POD, and only individuals with pre-CI will be eligible to continue in the study.
Phase I will establish the prevalence of POD and pre-CI in our patient population at Sunnybrook Health Sciences Centre, a tertiary care academic health sciences centre, and act as a control group for Phase II. Phase II will evaluate the effects of a comprehensive delirium-risk prevention bundle, which includes direct-to-patient education and healthcare provider awareness strategies. Participants in both Phase I and Phase II will provide written/verbal informed consent.
In each phase the study team will complete delirium assessments for 130 patients at baseline and on postoperative days 1-3. Demographic and clinical data will be abstracted from participants medical records. PHQ-9 (depression) and AD-8 (dementia screening interview) questionnaires will be completed at baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard of care
Multicomponent delirium-risk prevention bundle
Other: Multicomponent delirium-risk prevention bundle
This multidisciplinary intervention will introduce new practices including: 1. Direct-to-Patient Education Program 2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation 3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols). 4. Reinforce CHASM best practices with regular educational sessions for nurses.
Incidence of POD before and after implementation of an institutional prospective diagnostic program.
POD evaluated by 3D-CAM and retrospectively using the CHART-DEL method
Time frame: twice daily on postoperative days 1-3, morning/late afternoon
Delirium Severity
Assessed using CAM-S
Time frame: twice daily on postoperative days 1-3, morning/late afternoon
Hospital length of stay
Duration of hospital admission in days
Time frame: Until discharge, average of 1 week
Unit adherence rate to CHASM principles
Unit adherence rate to CHASM principles
Time frame: Until discharge, average of 1 week
Plan to share: Yes — All de-identified participants data collected during this trial that underlie the results reported in the publication(s) will be available upon request after publication of the primary results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available upon request immediately after publication of the primary results. No end date.
Access criteria: Direct request to PI. Anyone who wishes to access the data.
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2025, 48 months after the start.
Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 48 months is above that.
Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sunnybrook Health Sciences Centre →